CAMBRIDGE, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced additional information from its clinical development program for ferumoxytol as an intravenous treatment of iron deficiency anemia in patients with chronic kidney disease (CKD). The Company will host a conference call on January 31, 2007 at 9:00 am ET to discuss this additional information.
